Ascendis Pharma
$227.31Change from previous close: −0.23%Absolute change: −$0.52
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $14.96B
- Enterprise value
- $14.57B
- P/E (trailing 12 months)
- 17.7
- Forward P/E
- 20.8
- Price/book
- 9.16
- Price/sales
- 14.3
- EV/EBITDA
- 55.3
- EV/revenue
- 13.9
Profitability and growth
- Gross margin
- 91.3%
- Operating margin
- 65.0%
- Net margin
- 70.8%
- ROE
- 118.8%
- ROA
- 9.6%
- Revenue growth (year over year)
- 114.7%
Financial health
- Total cash
- $812.26M
- Total debt
- $450.07M
- Debt/equity
- 0.31
- Current ratio
- 2.99
- Quick ratio
- 2.23
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $306.44
- Median price target
- $313.12
- High price target
- $350.69
- Low price target
- $262.84
- Analysts with a price target
- 20
- Consensus
- Strong buy
- Forward EPS
- $10.90
- EPS estimate, current year
- $12.79
Shares and trading
- Average volume
- 644.09K
- Shares outstanding
- 65.8M
- Float
- 65.64M
- Institutional ownership
- 104.0%
- Insider ownership
- 0.8%
- Short interest (% of float)
- 7.1%
- Short ratio (days)
- 6.31